https://www.yiliao.com/index.php?action=history&feed=atom&title=T-DM1
T-DM1 - 版本历史
2026-04-28T17:26:46Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=T-DM1&diff=312855&oldid=prev
223.160.136.162：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-04T06:35:01Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>恩美曲妥珠单抗</strong>（<strong>Trastuzumab Emtansine</strong>，简称 <strong>T-DM1</strong>，商品名：<strong>赫赛莱/Kadcyla</strong>）是全球首个获批用于治疗实体瘤的 <strong>[[抗体偶联药物]] (ADC)</strong>。该药由靶向 <strong>[[HER2]]</strong> 的人源化单抗（曲妥珠单抗）通过稳定的硫醚连接子（MCC）与微管抑制剂 <strong>[[DM1]]</strong> 共价偶联而成。T-DM1 结合了抗体的靶向特异性与细胞毒性药物的高效杀伤力，通过受体介导的内吞作用在肿瘤细胞内部精确释放毒素。2026 年临床共识将其确立为 HER2 阳性早期乳腺癌患者在新辅助治疗后未达病理完全缓解（non-pCR）时的标准强化辅助治疗方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">恩美曲妥珠单抗</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Trastuzumab Emtansine (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[Image: Structure of T-DM1 showing Trastuzumab linked to DM1 molecules]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">HER2 靶向 ADC (DAR 3.5)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">主要靶点</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>HER2 (ERBB2)</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">载药 (Payload)</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">DM1 (Maytansinoid)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">连接子 (Linker)</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">MCC (不可切割型)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">载药比 (DAR)</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">~3.5</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS 登记号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1018448-65-1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方案</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>3.6 mg/kg Q3W</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">Molecular Weight</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">~148 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">原研厂商</th><br />
<td style="padding: 6px 12px; color: #0f172a;">Roche (罗氏)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：溶酶体依赖的精准爆破</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
T-DM1 的作用机制体现了 ADC 的经典“特洛伊木马”策略：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>受体介导的内吞：</strong> <br />
T-DM1 结合 HER2 胞外域 IV，通过受体介导的内吞作用进入细胞形成内吞体。</li><br />
<li style="margin-bottom: 12px;"><strong>不可切割连接子的特异性：</strong> <br />
由于 MCC 连接子不可被蛋白酶切割，药物必须转运至溶酶体。抗体部分被彻底降解后，释放出含有氨基酸残基的活性片段 <strong>[[Lys-MCC-DM1]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>微管蛋白抑制：</strong> <br />
DM1 通过结合微管蛋白，抑制微管聚合，使细胞周期阻断在 <strong>G2/M 期</strong>，诱导凋亡。</li><br />
<li style="margin-bottom: 12px;"><strong>保留的单抗效应：</strong> <br />
T-DM1 依然保留了曲妥珠单抗的 <strong>[[ADCC]]</strong> 效应和信号阻断功能。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：早期强化的金标准</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床地位</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">关键试验 (Evidence)</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">2026 临床获益</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">早期辅助强化</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>KATHERINE 研究</strong></td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">non-pCR 患者术后序贯 T-DM1，疾病复发风险降低 50%。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">转移性二线</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>EMILIA 研究</strong></td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">显著优于拉帕替尼+卡培他滨，现正逐步被 T-DXd 替代。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">安全性特征</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">临床监测数据</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">血小板减少 ($ \approx 14\% $) 与转氨酶升高是主要不良反应。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：安全性监控与序贯选择</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>血小板监测：</strong> DM1 载药具有显著的巨核细胞毒性，治疗前及每周期必须检查血小板计数。</li><br />
<li style="margin-bottom: 12px;"><strong>肝脏毒性：</strong> 基线有肝功受损者需谨慎。</li><br />
<li style="margin-bottom: 12px;"><strong>心脏安全性：</strong> 继承了曲妥珠单抗的心脏毒性风险，需每 3 个月监测 <strong>[[LVEF]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>ADC 迭代逻辑：</strong> 2026 年临床趋势显示，T-DM1 更多集中于早期治愈性阶段，而 <strong>[[T-DXd]]</strong> 则因其“旁观者效应”在晚期及低表达人群中占优。</li><br />
</ul><br />
<br />
<div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 8px; padding: 15px 20px; background-color: #f8fafc;"><br />
<h3 style="margin-top: 0; color: #0f172a; font-size: 1.1em;">关键相关概念</h3><br />
<p style="color: #334155; font-size: 0.95em; margin-bottom: 0;"><br />
[[HER2]] • [[抗体偶联药物 (ADC)]] • [[T-DXd]] • [[KATHERINE 研究]] • [[DM1 载药]] • [[病理完全缓解 (pCR)]] • [[赫赛汀]]<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>von Minckwitz G, et al. (2019).</strong> <em>Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>. 2019;380(7):617-628.<br />
</p><br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Verma S, et al. (2012).</strong> <em>Trastuzumab emtansine for HER2-positive advanced breast cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>. 2012;367(19):1783-1791.<br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
恩美曲妥珠单抗 (Kadcyla) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心构成</td><br />
<td style="padding: 10px 15px; color: #334155;">[[曲妥珠单抗]] • [[MCC 连接子]] • [[DM1 细胞毒素]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">优势场景</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Early Breast Cancer]] • [[Residual Disease]] • [[non-pCR 强化]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">同类演进</td><br />
<td style="padding: 10px 15px; color: #334155;">[[T-DXd (DS-8201)]] • [[ARX788]] • [[伊尼妥单抗]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.162